Rate My Professor Kathleen Boyd

Professor Kathleen Boyd is the Professor of Health Economics and Director of Research for the Health Economics & Health Technology Assessment (HEHTA) group in the School of Health & Wellbeing at the University of Glasgow. She holds a BA (Hons) in Economics from the University of Strathclyde, an MSc in Economics and Health Economics from the School of Health and Related Research (ScHARR) at the University of Sheffield, a Postgraduate Certificate in Academic Practice, and a PhD in Health Economics from the University of Glasgow. Her research specializations encompass health technology assessment (HTA), including decision analytic modelling, early stage and pre-trial modelling, designing and undertaking economic evaluations alongside clinical trials, HTA for complex and public health interventions, and value of information analysis. She maintains a track record in oncology, smoking cessation interventions, obstetrics, early years and child health, diagnostics, medical devices, mental health, social care interventions, and public health.

Boyd leads the economic evaluation alongside clinical trials theme within HEHTA, collaborating on multidisciplinary health care research projects throughout the UK and internationally. She serves as Lead Health Economics Reviewer for the Scottish Medicines Consortium (SMC) New Drugs Committee, informing decision-making policy in Scotland. She provides expert reviews for the National Institute for Health Research (NIHR), Medical Research Council (MRC), and Cancer Research UK, along with funding panel membership. Boyd is an advisory board member for the Beatson CRUK Clinical Trials Unit at Glasgow and a steering committee member for NIHR research programmes (HTA 152682, HTA 134350, HTA 134101, HA 127408, HSR 16/144/05) and the Academy of Medical Sciences Roundtable on Child Health Policy. Key publications include 'Effect of financial voucher incentives provided with UK stop smoking services on the cessation of smoking in pregnant women (CPIT III): pragmatic, multicentre, single blinded, phase 3, randomised controlled trial' (BMJ, 2022), 'A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance' (BMJ, 2021), 'Implementation of a national smoke-free prison policy: an economic evaluation within the Tobacco in Prisons (TIPs) study' (Tobacco Control, 2023), 'Economic evaluation of robotic assisted surgery: methods, challenges and opportunities' (Applied Health Economics and Health Policy, 2025), and 'Infant mental health services for birth and foster families of maltreated pre-school children in foster care (BeST?): a cluster-randomized phase 3 clinical effectiveness trial' (Nature Medicine, 2025).